MLYS Stock Risk & Deep Value Analysis

Mineralys Therapeutics, Inc.

DVR Score

7.8

out of 10

Solid Pick

The Bottom Line on MLYS

We analyzed Mineralys Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran MLYS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 21, 2025•Run Fresh Analysis →

📈MLYS Performance Overview3yr weekly

📊

Unlock MLYS Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

MLYS Deep Value Analysis

Mineralys Therapeutics (MLYS) presents a high-risk, high-reward opportunity, driven by its lead asset, lorundrinerant, targeting the substantial and underserved uncontrolled hypertension market with a novel mechanism. The pivotal Phase 3 data expected in Q4 2024 is a significant, binary catalyst offering 10x potential if successful. The company exhibits strong leadership, a clear strategic vision, and sufficient capital runway post-recent raise. While not a 'dud' due to a differentiated offering and strategic progress, the primary risk is clinical trial failure, which could lead to substantial value loss. This is an early-stage, speculative play reliant on successful trial outcomes.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on MLYS

Create a free account to set price alerts and get notified on Telegram when MLYS hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Mineralys Therapeutics, Inc. (MLYS)?

As of September 21, 2025, Mineralys Therapeutics, Inc. has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the MLYS DVR analysis updated?

Our AI-powered analysis of Mineralys Therapeutics, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 21, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.